{"name":"Zhejiang Hisun Pharmaceutical Co. Ltd.","slug":"zhejiang-hisun-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"hisunpharm.com","description":"","hq":"Taizhou","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"HS022","genericName":"HS022","slug":"hs022","indication":"Other","status":"phase_3"},{"name":"AST-3424","genericName":"AST-3424","slug":"ast-3424","indication":"Other","status":"phase_2"},{"name":"Ademethionine","genericName":"Ademethionine","slug":"ademethionine","indication":"Other","status":"marketed"},{"name":"Placebo of HS-25","genericName":"Placebo of HS-25","slug":"placebo-of-hs-25","indication":"Other","status":"phase_3"},{"name":"Polyene Phosphatidyl choline","genericName":"Polyene Phosphatidyl choline","slug":"polyene-phosphatidyl-choline","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"Ademetionine 1","genericName":"Ademetionine 1","slug":"ademetionine-1","indication":"Liver disease and cholestasis","status":"marketed"},{"name":"Ademetionine 2","genericName":"Ademetionine 2","slug":"ademetionine-2","indication":"Cholestasis and cholestatic liver disease","status":"marketed"},{"name":"Ademetionine 3","genericName":"Ademetionine 3","slug":"ademetionine-3","indication":"Liver disease and hepatic dysfunction","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"HS628+MTX","genericName":"HS628+MTX","slug":"hs628-mtx","indication":"Rheumatoid arthritis or other autoimmune inflammatory conditions (specific indication not publicly confirmed)","status":"phase_3"},{"name":"Actemra +MTX","genericName":"Actemra +MTX","slug":"actemra-mtx","indication":"Rheumatoid arthritis (moderate to severe, in combination with methotrexate)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"HS-25","genericName":"HS-25","slug":"hs-25","indication":"Treatment of type 2 diabetes","status":"phase_3"},{"name":"Placebe of HS-25 and Atorvastatin","genericName":"Placebe of HS-25 and Atorvastatin","slug":"placebe-of-hs-25-and-atorvastatin","indication":"Hypercholesterolemia","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"HS-25 and Atorvastatin","genericName":"HS-25 and Atorvastatin","slug":"hs-25-and-atorvastatin","indication":"Hyperlipidemia or cardiovascular disease (specific indication not publicly confirmed)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Vinorelbine Bitartrate","genericName":"Vinorelbine Bitartrate","slug":"vinorelbine-bitartrate","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_3"}]}],"pipeline":[{"name":"HS-25 and Atorvastatin","genericName":"HS-25 and Atorvastatin","slug":"hs-25-and-atorvastatin","phase":"phase_3","mechanism":"HS-25 is a combination therapy where HS-25 (an investigational agent) is co-administered with atorvastatin, a statin that inhibits HMG-CoA reductase to lower cholesterol.","indications":["Hyperlipidemia or cardiovascular disease (specific indication not publicly confirmed)"],"catalyst":""},{"name":"HS022","genericName":"HS022","slug":"hs022","phase":"phase_3","mechanism":"HS022 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.","indications":[],"catalyst":""},{"name":"HS628+MTX","genericName":"HS628+MTX","slug":"hs628-mtx","phase":"phase_3","mechanism":"HS628 is a small-molecule inhibitor combined with methotrexate (MTX) to target immune-mediated inflammatory conditions through dual pathway suppression.","indications":["Rheumatoid arthritis or other autoimmune inflammatory conditions (specific indication not publicly confirmed)"],"catalyst":""},{"name":"AST-3424","genericName":"AST-3424","slug":"ast-3424","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Actemra +MTX","genericName":"Actemra +MTX","slug":"actemra-mtx","phase":"phase_3","mechanism":"Actemra (tocilizumab) is an IL-6 receptor antagonist that blocks interleukin-6 signaling to reduce inflammatory responses, used in combination with methotrexate (MTX) for rheumatoid arthritis.","indications":["Rheumatoid arthritis (moderate to severe, in combination with methotrexate)"],"catalyst":""},{"name":"Ademethionine","genericName":"Ademethionine","slug":"ademethionine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ademetionine 1","genericName":"Ademetionine 1","slug":"ademetionine-1","phase":"marketed","mechanism":"Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function.","indications":["Liver disease and cholestasis","Hepatic dysfunction","Drug-induced liver injury"],"catalyst":""},{"name":"Ademetionine 2","genericName":"Ademetionine 2","slug":"ademetionine-2","phase":"marketed","mechanism":"Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function.","indications":["Cholestasis and cholestatic liver disease","Hepatic dysfunction and liver support","Drug-induced liver injury"],"catalyst":""},{"name":"Ademetionine 3","genericName":"Ademetionine 3","slug":"ademetionine-3","phase":"marketed","mechanism":"Ademetionine is a methyl donor that replenishes cellular S-adenosylmethionine (SAM) levels to support methylation reactions and hepatic function.","indications":["Liver disease and hepatic dysfunction","Cholestasis","Hepatic cirrhosis"],"catalyst":""},{"name":"HS-25","genericName":"HS-25","slug":"hs-25","phase":"phase_3","mechanism":"HS-25 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"Placebe of HS-25 and Atorvastatin","genericName":"Placebe of HS-25 and Atorvastatin","slug":"placebe-of-hs-25-and-atorvastatin","phase":"phase_3","mechanism":"Atorvastatin is a statin that inhibits HMG-CoA reductase to lower cholesterol levels.","indications":["Hypercholesterolemia","Hyperlipidemia"],"catalyst":""},{"name":"Placebo of HS-25","genericName":"Placebo of HS-25","slug":"placebo-of-hs-25","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Polyene Phosphatidyl choline","genericName":"Polyene Phosphatidyl choline","slug":"polyene-phosphatidyl-choline","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vinorelbine Bitartrate","genericName":"Vinorelbine Bitartrate","slug":"vinorelbine-bitartrate","phase":"phase_3","mechanism":"Vinorelbine bitartrate is a semi-synthetic vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting cell division and inducing apoptosis in cancer cells.","indications":["Non-small cell lung cancer (NSCLC)","Breast cancer","Ovarian cancer","Hodgkin lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNOGw2Y3JueVhZYnRLQ2d5REdLT243NG9JSGxycmhDaUN2eVlfR1BqWHNWdThJbmhCUWlhT2pielo0MFVrN1ZhZm9hSXFqMTlIRDQxVXB0TV9lQzNrSVpMbGhOXzFkbEEtU1drR3ktcnlwNnhxMmJUcml5S1VDRm5tR0hKWQ?oc=5","date":"2026-01-04","type":"deal","source":"Insilico Medicine","summary":"AI-Powered R&D Acceleration: Insilico Medicine and Hisun Pharma Nominate a Preclinical Candidate Just 8 Months After Forming a Strategic Collaboration - Insilico Medicine","headline":"AI-Powered R&D Acceleration: Insilico Medicine and Hisun Pharma Nominate a Preclinical Candidate Just 8 Months After For","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPU2Y2VVFHN1k1djU2SEVIbnVsQ0xvT04zNGktcTloUGVPcHhOb0FNTHlmSFJhMUdCQWt3OG9mSHNVaWxSOFE2bnhoZmNmNkNlNnFUd25OYXRuREM4WHBQTmdNQXNIMGJITjhBZFlEYXhWaUJWdEJWVDc0UnFPUlNfNHRHbkdRcnFMcFE?oc=5","date":"2025-02-20","type":"pipeline","source":"Global Growth Insights","summary":"Atorvastatin-API Market Size, Trends & CAGR, 2035 - Global Growth Insights","headline":"Atorvastatin-API Market Size, Trends & CAGR, 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPYXFwZ3BwV3JmVkVSakFUUnpaQVhFcFdseXlEY3RIUUdTMFVlaC1HR0RuQkhYSDYzQW1UcGU3R2pHOGZOUHhKUjdtQ3FPQzcwY1VVLWJPOUFjZUdkS3FVSExlRUJmdlNaZHJTNDB1bktlMHVwQ04xdnoxQTI5WWg2MnJ1UmZ5NGUxMnVqbS13dzdKdUZ5RlZNS2xoWVVRWmpPRTBpbUZLMF9SVVFXYWRJeXlZYkRqd2NBXzV0OE9wU1p4YXM1enVtbl9zRElqQjhpX0swUldGcy0xTlRXbU5lbG9HeXhreEg3elllYW1Hc2RSY3pTU3ZWWEVIYWE1NV90Uld3X05vbXQ?oc=5","date":"2022-07-26","type":"pipeline","source":"prnewswire.com","summary":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsight - prnewswire.com","headline":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNYTIzcTVUMVlUVTJ4czFmOFJYLXl3MHNueVNXb1l1ZjRNbDZwc1NvMkllcTE3OFZWYXdKQWhFbjFybkMyeHp6ZS1mZ2F2SXJNUXhPdTE0aVdhZjBzTjBvRkRuZXRRdmJiUXJTYXZFdmluU3F2ZDFOcGNVWEY3RHgwQ2xCTDZ0YklsV0F6WUUtS2JxMU02Ry0td2todXd2TlRCTEtLNDlhTGxGdjc3QTBhZFhxQ3ZDQ3VGOXNpdWF1bTRhN1FMMnNra1FNX1UxT3JYTEoxRV9zeDQ4SHkt?oc=5","date":"2020-06-26","type":"pipeline","source":"Business Wire","summary":"Zhejiang Hisun Pharmaceutical Co., Ltd.: Free of COVID-19, Governments Suggest Favipiravir - Business Wire","headline":"Zhejiang Hisun Pharmaceutical Co., Ltd.: Free of COVID-19, Governments Suggest Favipiravir","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5DLVBmTzBJVzdFczNmeXpCMS1OeVpnbmNpLTB4MTVRODBXRTVaX2J4QkM1OEpTQjR3OVlmR0gyVXhGcXZwNGhBQk1CQWFfWDdE?oc=5","date":"2020-03-20","type":"pipeline","source":"The Edge Malaysia","summary":"Flu drug Favipiravir is effective in treating COVID-19 - The Edge Malaysia","headline":"Flu drug Favipiravir is effective in treating COVID-19","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxPVm9YU1JzN3JQRjdfckppSzREZDhWWEk3RUxjd0dzZGMteVBfOW96a1N6ZHJJejZSUEJpcnlpYnc5TnozZ0hBdVdzZzlfUXA2bzFId2VVdEZaVzNjX1lIUzdhWmVLOXdjcklsS0o2bldQRXV3N3dOVlJVOEFxcjdmck1GOE1pRVAwSnRWT0hydWVLR3laU2JMbGY2dmR2RXkzaUdIXzlnVFZvbmZGU3N2WV9UU05qSzhIdTJORm9LbjR2cWFoYWJKbjlSMXp6a1NQVGx1Z1lETFo2UHAxTWhHWTVxQnkyVmFUdmZkTUIzN2trZlZ0SHY4SzRpZVB1M0RESC11U0NhRXA4OUxfbmwzSTVJcldxUQ?oc=5","date":"2020-03-19","type":"pipeline","source":"prnewswire.com","summary":"Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients - prnewswire.com","headline":"Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQZkx2RWUxVFpEZHBHVm9nRi1xRFdDeENuTnRRXy1sNWtBTGZZc1lseVNWanhzaDBqelQ2dFNyNmpGYUhnV1prNDBxOUdGWjhQV3FqTTNpbGhSanFQTTE2QW4zLV9JSVNVcVR3bW4xZGlQcmRBcFc1azdYYzh3YjhfQnJIRmUtS0FhbW0xUkZtWlYwQQ?oc=5","date":"2017-12-08","type":"pipeline","source":"Citeline News & Insights","summary":"Hisun-Pfizer Split: What Went Wrong And What Next? - Citeline News & Insights","headline":"Hisun-Pfizer Split: What Went Wrong And What Next? - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOWVVBQm44UXNQWERqTnNCd1B6bkVfeUJtX2VNbkZfZUdoN2JkM0k0RWdWRmc3SXZGek5LN1dZVzZPc3c4QVJVMlR2b29fRVBQc1JOaGNERXVWRDNLNU1zdFd5cVdUV3ZpSTEyZ013cGtDUVJjcDJDS1oxeGRsQ3h5ajZwNmxzb1RGN2xDdWV5N3R2R2Z0aWdLcEIwVUJtWVplLVlCckozQ3ZzRVRxWHJSS0V1Yw?oc=5","date":"2017-11-10","type":"pipeline","source":"Bloomberg.com","summary":"Pfizer Sells Stake in China's Hisun, Ending Drugs Joint Venture - Bloomberg.com","headline":"Pfizer Sells Stake in China's Hisun, Ending Drugs Joint Venture","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZmozRS1QMDFaTE9LbU9wd0hyV05hUVVMeVJiZDFBQXRiUnJJRXZ0RmFZR0s1eHUtTGpNRGVpckdWYnEtX1VxMmRyTURtR254YmRiV2lfTW9xeGsyYjdnUlAzcVE1M3FBcUtsa0kzRnZ1NWxNX19iZlVsWWpfUHhnaHlteXBQRlRXamoyV0hHQ2V1VzFsNUxNWDB3d2NmMTdZSHM2UWJfOFc2dEhlNnB5cmY4aFFzdDV2?oc=5","date":"2016-07-25","type":"regulatory","source":"Fierce Pharma","summary":"U.S. FDA ingredient exceptions from banned Zhejiang Hisun plant draw scrutiny - Fierce Pharma","headline":"U.S. FDA ingredient exceptions from banned Zhejiang Hisun plant draw scrutiny","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOdmZlN2FoYjk2UlBZNG9JdW9uZENla095VUdGamZtQ0lNelVEOG55UnAtMERuME1GYjVRcFhkQ21Pc0ZobHczUXNVR0p3MldyZjhjSHB4ekJWUEpDX01keUh3N3dKUW9ILWhGTDN0OWhhNGhQZ0xyaHlSc05hbVBndWxFZDhMSktkR1Zla0kzZ3YzRnFtcHpYNXFUX1RoSDdSSmdmX2hJQmR1ckdnb3c?oc=5","date":"2016-02-10","type":"regulatory","source":"raps.org","summary":"US FDA Inspections in China: An Analysis of Form 483s from 2015 - raps.org","headline":"US FDA Inspections in China: An Analysis of Form 483s from 2015","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNYVFMX245TFFfYVl2Yk4wMTFaWmhkNElGaW5IQWVlUEtKdlp2ZWR0Q0hvSnV3UWtMa2E1eVVaY0JpUEpTT3c1NUFpT0Joa0RfTGx5dDhxZGprYVRqa3RKYkxzR3lUOF9OempNaGRHUE9LMVhKVTNqZ0ZJeGhvNzVUOE93QVRlaDNGWV80WjJfaEVYYWFKdkNMY1pPendzdFRIa2FYYXJFMnpqdw?oc=5","date":"2015-03-03","type":"pipeline","source":"The Business Journals","summary":"Photolitec lands $2M investment from Indian pharma giant - The Business Journals","headline":"Photolitec lands $2M investment from Indian pharma giant","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_3":8,"phase_2":1,"marketed":5},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}